New Advances in Arbovirus Vaccines
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 2477
Special Issue Editor
Interests: virus evolution and transmission; arboviruses; vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Arboviruses, predominantly transmitted by arthropods, like mosquitoes and ticks, represent a significant public health concern globally. With notorious representatives, such as Dengue, Zika, Chikungunya, Yellow fever, and West Nile viruses, their prevalence and potential for epidemic outbreaks have intensified the urgency for effective preventative measures. At this moment, there is no specific treatment, and there are few licensed vaccines to fight these viruses. The complex landscape of vaccine development is further riddled with challenges like immune enhancement, cross-reactivity, and the adaptive nature of these viruses. Recently, novel platforms, such as mRNA, subunit, virus-like particle, and insect-specific vaccines, have shown promising potential. This Special Issue underscores the progression and evaluation of new vaccine candidates against arboviruses, with special focus on vaccines developed using new strategies. Submissions of original research articles and reviews are welcome, but not limited, to the following diseases: Dengue, Chikungunya, Zika, Yellow fever, Japanese encephalitis, West Nile, Equine Encephalitis and Crimean–Congo haemorrhagic fever virus.
Dr. Jianying Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- arboviruses
- vaccine development
- antibody-dependent enhancement
- cross-reactivity
- mRNA vaccines
- insect-specific vaccines
- virus-like particle
- transmission-blocking vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
